Cosmo Holdings, Virax Biolabs up on marketing agreement for monkeypox test
22/09/2022 14:34
** Shares of Virax Biolabs Group Ltd VRAX.O rise 14.8% to
$3.5, while shares of Cosmos Holdings Inc COSM.O surge 36.2%
to $0.32 before the market
** VRAX says its entered in distribution agreement to market
its monkeypox Virus rapid antigen test kits with COSM
urn:newsml:reuters.com:*:nPn2xGTzTa
** Under the agreement, COSM will have exclusive right to
sell monkeypox test kits in Greece and Cyprus, and can also sell
kits in other European nation on non-exclusive basis
** VRAX had launched monkeypox virus antigen rapid test kit
in markets accepting CE mark, which is a manufacturer's
declaration test complies with European norms, on Monday
urn:newsml:reuters.com:*:nL4N30R2TI
** Up to Wednesday's close, stock of VRAX stock down ~39%
from its July IPO price of $5; COSM lost ~93% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))